Original articlesInvolvement of corticotropin-releasing factor subtype 1 receptor in the acquisition phase of learned helplessness in rats
References (0)
Cited by (28)
Behavioral, biological, and chemical perspectives on targeting CRF<inf>1</inf> receptor antagonists to treat alcoholism
2013, Drug and Alcohol DependenceCitation Excerpt :Antalarmin, CP-154,526, DMP904, R121919, DMP696, and R278995 did not produce antidepressant-like effects in the mouse tail-suspension test (Chaki et al., 2004; Liu et al., 2003; Nielsen et al., 2004). Although CRF1 antagonist treatment was initially reported to reverse “learned helplessness” (Mansbach et al., 1997), subsequent studies with CP-154,526, DMP904, DMP696, R2789995, and CRA1000 failed to replicate this finding (Chaki et al., 2004; Li et al., 2005; Takamori et al., 2001). Finally, R278995 did not produce antidepressant-like effects in the rat differential-reinforcement-of-low-rate 72-s model (Chaki et al., 2004).
Therapeutic utility of non-peptidic CRF<inf>1</inf> receptor antagonists in anxiety, depression, and stress-related disorders: Evidence from animal models
2010, Pharmacology and TherapeuticsCitation Excerpt :Antidepressant effects of either acute or chronic (8 days) dosing with CRA0450 decreased escaped failures in the rat learned helplessness test (Takamori et al., 2001). CP-154,526 was also effective in this test (Takamori et al., 2001). It should be noted that one study reported that antalarmin administered both prior to training and testing was ineffective in reversing the shuttlebox avoidance deficits resulting from exposure 24 h earlier to inescapable tail shock (Deak et al., 1999).
Progress in corticotropin-releasing factor-1 antagonist development
2010, Drug Discovery TodayHypothalamus-pituitary-adrenal modifications consequent to chronic stress exposure in an experimental model of depression in rats
2007, NeuroscienceCitation Excerpt :The increased CRH functional activity ensuing from the decreased glucocorticoid negative feedback could play a crucial role in the acquisition and consolidation of escape deficit behavior. The central role exerted by CRH through activation of CRHR1 receptors is supported by results showing that the administration of CRHR1 antagonists significantly decreases the number of escape failures induced by inescapable stress exposure (Takamori et al., 2001a; Chaki et al., 2004). Takamori et al. (2001b) also showed that the protective effects of the repeated administration of CRHR1 antagonists as well as of IMI, are reversed by exogenous ACTH administration.
The role of CRF receptors in anxiety and depression: Implications of the novel CRF<inf>1</inf> agonist cortagine
2005, Neuroscience and Biobehavioral ReviewsCitation Excerpt :In addition, a variety of synthetic non-peptidic CRF1-selective antagonists have been studied in animal models of depression (for review, see Kehne and De Lombaert, 2002). For example, antidepressant-like activity has been shown with CP-154,526 in the learned helplessness paradigm (Mansbach et al., 1997; Takamori et al., 2001). Similarly, antalarmin exhibits antidepressant-like activity in the rodent forced swim test (Griebel et al., 2002; Bale and Vale, 2003), as do R121919 and DMP696 in the tail suspension test (Nielsen et al., 2004).